- Results from a Phase 3 clinical trial, ARCHES, evaluating Pfizer (NYSE:PFE) and Astellas Pharma's (OTCPK:ALPMF) XTANDI (enzalutamide) plus standard hormonal therapy in men with metastatic hormone-sensitive prostate cancer met the primary endpoint of demonstrating a statistically significant reduction in the risk radiographic progression or death by 61% compared to androgen deprivation therapy alone (hazard ratio = 0.39; p<0.0001). The data will be presented at the ASCO GU Cancers Symposium in San Francisco.
- The companies plan to review the data with global regulatory authorities to support marketing applications for the new indication.